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shows numerous broken hairs. Beaded hairs pathognomic
of monilethrix can be seen.INTRODUCTION
Monilethrix is an autosomal dominant genoder-
matosis characterized by hair fragility, keratosis
pilaris, and pathognomonic beading of the hair shaft.
Hair fragility may lead to hair breakage and the
appearance of generalized hair loss.1
The gene for autosome-dominant monilethrix has
been mapped to the epithelial keratin gene cluster on
12q13,2 and point mutations have been found in the
hair cortexespecific keratin genesKRT86,KRT83, and
KRT81.3,4 Mutations in desmoglein 4 are responsible
for an autosomal recessive variant of monilethrix.5
Monilethrix has considerable inter- and intrafami-
lial variations in age of onset, severity, and natural
history.4 Most often, hair is normal at birth and is
progressively replaced by short, fragile, brittle hair
during the first months of life. Hair breakage
secondary to hair fragility may be accompanied by
follicular keratosis most commonly on the occiput.
Friction from wigs and their adhesives may
exacerbate hair loss. Eyebrows, eyelashes, pubic,
axillary, and general body hair may be affected along
with the scalp.
In most patients, the hair loss persists with little
change throughout life. Spontaneous improvement
or complete recovery has been reported during
pregnancy.6
There is no cure for monilethrix. Reduction in
hairdressing trauma may diminish weathering and
improve severely affected cases.1 Two women with
monilethrix who responded to 6months of treatment
with low-dose oral minoxidil are described.CASE SERIES
Case 1
A 40-year-old woman presented with lifelong
fragile, sparse, and thin hair. She had monilethrixthe University of Melbourne, Department of Medicine,
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m.au.diagnosed in childhood. She reported striking
improvement in hair volume and length during
each pregnancy but relapsed within 12 months
postpartum.
Comorbidities included Crohn’s disease and
impaired hearing. Her daughter and 2 sons also
had monilethrix and suffered from sparse and fragile
hair.
On examination, she had brittle, lustreless, fragile,
short hair all over the scalp. Her hair turned to
powder when rolled between fingers. She was noted
to have small keratotic papules on the nape of the
neck. There were no nail or tooth abnormalities
detected. Dermoscopy (Fig 1) confirmed the
diagnosis of monilethrix.
Treatment started with oral minoxidil, 0.25 mg
daily. Review after 6 months found significant hair
growth with reduced breakage and increased hair
volume and length (Fig 2). The patient did not
experience any side effects or complication of the
treatment. The patient continued on the treatment
and is reviewed at 3-month intervals. The initial
improvement in hair density has been maintainedJAAD Case Reports 2016;2:212-5.
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Fig 2. Patient 1. Monilethrix. Lateral and posterior views of the scalp before and after 6 months
of treatment with low-dose oral minoxidil.
Fig 3. Patient 2. Dermascopic image of the mid-frontal
scalp shows broken hairs. Beaded hairs pathognomic of
monilethrix can be seen.
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additional follow-up.
Case 2
A 35-year-old woman with fragile, thin, and
sparse hair since childhood secondary tomonilethrix
presented for assessment and treatment. She had a
positive family history of monilethrix affecting her
son, daughter, and grandson.Examination found brittle, lustreless, fragile short
hair all over the scalp, keratotic papules on the
occipital scalp, and keratosis pilaris. No nail or dental
abnormalities were present. Dermoscopy found
elliptical nodes separated by narrower internodes
(Fig 3).
She started oral minoxidil, 0.25 mg daily. On
examination 3 months after the initial consultation,
hair shedding decreased significantly. However, the
hair density remained unchanged. Minoxidil was
increased to 0.5 mg daily. There was a significant
improvement in hair density on review at 6 months
(Fig 4).
The patient remains on the treatment and is
reviewed at 3-month intervals. The initial improve-
ment in hair density has been maintained, and no
side effects have emerged after 18 months of
additional follow-up.DISCUSSION
Monilethrix is a hair shaft fragility genodermato-
sis. Etretinate is found to reduce hair beading but
Fig 4. Patient 2 is less severely affected than patient 1. Lateral and mid-frontal views of the
scalp before and after 6 months of treatment with low-dose oral minoxidil.
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Topical minoxidil 2% has been used to treat
monilethrix. Saxena et al8 treated 3 sisters with 2%
monilethrix solution twice daily and noted a
reduction in fragility after 2.5 months and increased
hair length at 6 months. Rossi et al9 treated 4 patients
for 12 months with similar effects.
Minoxidil is known to induce hypertrichosis,
prolong anagen duration, and increase hair
diameter.8 Because the application of topical
minoxidil can leave the hair dry and tangled and
could potentially accentuate breakage of fragile
hairs, both patients were treated off-label with
low-dose oral minoxidil.
Little is known about the pharmacologic interaction
between minoxidil and target cells in hair follicles.
Several ways in which minoxidil could stimulate hair
growth include increasing the linear growth rate of
hair, increasing the diameter of the hair fiber, alteringthe hair cycle by either shortening of telogen or
prolonging anagen, or a combination of these.10
Histologic studies show that treatment with
minoxidil causes an increase in the proportion of
follicles in anagen, a reduction in telogen follicles,
and an increase in hair follicle size. It is also effective
on proliferation and differentiation of normal human
keratinocyte.10
Oral minoxidil is a promising treatment for hair
loss associated with monilethrix. When used in low
doses it appears to be well tolerated. Based on
observations in male and female pattern hair loss, it
is likely that that long-term maintenance treatment
will be required to prevent relapse of hair loss.
Patients receiving long-term treatment should have
regular monitoring of their blood pressure and pulse
rate, as oral minoxidil has been associated with
postural hypotension and tachycardia. Generally,
these side effects and fluid retention are only seen at
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Sinclair 215higher dosages. Facial hypertrichosis can occur with
both oral and topical minoxidil. Facial hypertrichosis
is dose related, and whenmild is easily managed with
waxing, depilatory creams, or laser hair removal.
Further studies are required to document safety
and efficacy.
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